Metabolic Reprogramming of Mammary Epithelial Cells during TGF-β-Induced Epithelial-to-Mesenchymal Transition.

NMuMG breast cells TGF-β choline kinase α (CHKα) epithelial-to-mesenchymal transition (EMT) metabolism

Journal

Metabolites
ISSN: 2218-1989
Titre abrégé: Metabolites
Pays: Switzerland
ID NLM: 101578790

Informations de publication

Date de publication:
15 Sep 2021
Historique:
received: 09 07 2021
revised: 30 08 2021
accepted: 04 09 2021
entrez: 26 9 2021
pubmed: 27 9 2021
medline: 27 9 2021
Statut: epublish

Résumé

The cytokine transforming growth factor-β (TGF-β) can induce normal breast epithelial cells to take on a mesenchymal phenotype, termed epithelial-to-mesenchymal transition (EMT). While the transcriptional and proteomic changes during TGF-β-induced EMT have been described, the metabolic rewiring that occurs in epithelial cells undergoing EMT is not well understood. Here, we quantitively analyzed the TGF-β-induced metabolic reprogramming during EMT of non-transformed NMuMG mouse mammary gland epithelial cells using nuclear magnetic resonance (NMR) spectroscopy. We found that TGF-β elevates glycolytic and tricarboxylic acid (TCA)-cycle activity and increases glutaminolysis. Additionally, TGF-β affects the hexosamine pathway, arginine-proline metabolism, the cellular redox state, and strongly affects choline metabolism during EMT. TGF-β was found to induce phosphocholine production. A kinase inhibitor RSM-93A that inhibits choline kinase α (CHKα) mitigated TGF-β-induced changes associated with EMT, i.e., increased filamentous (F)-actin stress fiber formation and N-Cadherin mesenchymal marker expression.

Identifiants

pubmed: 34564442
pii: metabo11090626
doi: 10.3390/metabo11090626
pmc: PMC8464788
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Centre for Cancer Genomics Netherlands
ID : CGC.NL
Organisme : Chinese scholarship council
ID : CSC

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

FEBS J. 2017 Oct;284(20):3437-3454
pubmed: 28834297
Nat Commun. 2017 May 11;8:15267
pubmed: 28492237
Oncogene. 2002 Jun 20;21(27):4317-22
pubmed: 12082619
Nat Commun. 2014 Mar 03;5:3388
pubmed: 24584437
J Cell Physiol. 2002 Apr;191(1):1-16
pubmed: 11920677
Dev Cell. 2008 Jun;14(6):818-29
pubmed: 18539112
Nat Rev Cancer. 2002 Jun;2(6):442-54
pubmed: 12189386
Nucleic Acids Res. 1999 Jan 1;27(1):29-34
pubmed: 9847135
Mol Cell. 2013 Sep 12;51(5):559-72
pubmed: 23973329
Antioxid Redox Signal. 2019 Feb 1;30(4):635-649
pubmed: 28990419
Sci Rep. 2016 Nov 08;6:36289
pubmed: 27824159
Nat Rev Mol Cell Biol. 2018 Jul;19(7):419-435
pubmed: 29643418
J Natl Cancer Inst. 2015 Dec 11;108(5):
pubmed: 26657335
Breast Cancer Res. 2003;5(6):R187-98
pubmed: 14580254
Nature. 2017 Jul 6;547(7661):109-113
pubmed: 28658205
Cancer Metab. 2016 Oct 17;4:19
pubmed: 27777765
Curr Opin Genet Dev. 2011 Feb;21(1):93-9
pubmed: 21251810
Sci Adv. 2019 Nov 27;5(11):eaax7525
pubmed: 31807705
Cell. 2013 Aug 1;154(3):651-63
pubmed: 23911327
Dev Dyn. 2018 Mar;247(3):473-480
pubmed: 28795450
Proc Natl Acad Sci U S A. 2019 Aug 6;116(32):16105-16110
pubmed: 31341083
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
Nature. 2020 Jan;577(7791):566-571
pubmed: 31915377
EMBO J. 2020 Apr 15;39(8):e103334
pubmed: 32134147
Nat Rev Cancer. 2004 Nov;4(11):891-9
pubmed: 15516961
Cancer Metastasis Rev. 2012 Dec;31(3-4):553-68
pubmed: 22714591
Cancers (Basel). 2018 Oct 22;10(10):
pubmed: 30360374
Trends Cancer. 2017 Jan;3(1):56-71
pubmed: 28718426
Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15526-31
pubmed: 25313085
Nat Rev Mol Cell Biol. 2012 Oct;13(10):616-30
pubmed: 22992590
Biochem Biophys Res Commun. 2002 Aug 23;296(3):580-3
pubmed: 12176020
FEBS J. 2017 Oct;284(19):3132-3144
pubmed: 28444969
Nat Rev Cancer. 2018 Nov;18(11):681-695
pubmed: 30181570
Oncotarget. 2018 Jun 29;9(50):29468-29483
pubmed: 30034631
Front Oncol. 2017 Mar 14;7:40
pubmed: 28352611
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96
pubmed: 24556840
Oncogenesis. 2013;2:e38
pubmed: 25522435
Transl Oncol. 2016 Dec;9(6):512-520
pubmed: 27816688
Cell. 2008 Jul 25;134(2):215-30
pubmed: 18662538
Anal Chim Acta. 2017 Aug 8;980:1-24
pubmed: 28622799
Nat Rev Cancer. 2013 Feb;13(2):97-110
pubmed: 23344542
Curr Opin Cell Biol. 2018 Apr;51:1-7
pubmed: 29149681
Cell Tissue Res. 2002 Jan;307(1):1-14
pubmed: 11810309
Prog Lipid Res. 2016 Jul;63:28-40
pubmed: 27073147
Cell Death Differ. 2017 Jan;24(1):1-2
pubmed: 27886164
Cell Mol Life Sci. 2020 Jun;77(11):2103-2123
pubmed: 31822964
Oncotarget. 2016 Nov 8;7(45):73414-73431
pubmed: 27705917
Cold Spring Harb Perspect Biol. 2018 Mar 1;10(3):
pubmed: 28289061

Auteurs

Wan Hua (W)

Oncode Institute and Cell Chemical Biology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
Institute of Rare Diseases, West China Hospital, Sichuan University, Chengdu 610041, China.

Sarantos Kostidis (S)

Center for Proteomics and Metabolomics, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.

Oleg Mayboroda (O)

Center for Proteomics and Metabolomics, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.

Martin Giera (M)

Center for Proteomics and Metabolomics, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.

Marten Hornsveld (M)

Oncode Institute and Cell Chemical Biology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.

Peter Ten Dijke (P)

Oncode Institute and Cell Chemical Biology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.

Classifications MeSH